Glycogen Storage Disease, Type II
Reference54 articles.
1. ACMG Work Group on Management of Pompe Disease, Kishnani, P. S., Steiner, R. D., Bali, D., et al. (2006). Pompe disease diagnosis and management guideline. Genetics in Medicine, 8, 267–288. 2. Amalfitano, A., Bengur, A. R., Morse, R. P., et al. (2001). Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: Results of a phase I/II clinical trial. Genetics in Medicine, 3, 132–138. 3. Amalfitano, A., McVie-Wylie, A. J., Hu, H., et al. (1999). Systemic correction of the muscle disorder glycogen storage disease type II after hepatic targeting of a modified adenovirus vector encoding human acid-alpha-glucosidase. Proceedings of the National Academy of Sciences of the United States of America, 96, 8861–8866. 4. Amato, A. A. (2000). Acid maltase deficiency and related myopathies. Neurologic Clinics, 18, 151–165. 5. American Association of Neuromuscular & Electrodiagnostic Medicine. (2009). Diagnostic criteria for late-onset (childhood and adult) Pompe disease. Muscle & Nerve, 40, 149–160.
|
|